NodThera is treating chronic diseases by targeting inflammation at its source. There is a growing volume of literature linking the NLRP3 inflammasome as the upstream catalyst of inflammation driving many chronic diseases of the body and brain. NodThera is identifying NLRP3-inhibitors by using novel chemistry, translatable assays and proprietary in-house in vivo models. These small molecules have several advantages over other therapies as they can potentially penetrate many tissue types and cross the blood brain barrier. In addition by targeting only NLRP3 inflammasomes, it spares other inflammasomes to fight infection.

NodThera

Founded: 2016
Location: Lexington, MA
Employee range: 11 - 50
Clinical stage: Clin1
Therapy area: Peripheral and neuroinflammatory diseases
Drug types: NEU, IMM
Lead product: NT-0796
Funding: $55M B Jun 2020; £28M A Jun 2018

Drug notes:

About:

Jobs: